



Male

PATIENT NAME: VIRENDRA SINGH REF. DOCTOR: SELF

ACCESSION NO: **0002WK032379**AGE/SEX: 37 Years
VIRENDRA SINGH

PATIENT ID : VIREM2711852

CLIENT PATIENT ID: ABHA NO : DRAWN :25/11/2023 08:46:01 RECEIVED :25/11/2023 08:47:47 REPORTED :27/11/2023 12:14:42

Test Report Status Final Results Biological Reference Interval Units

## MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

**XRAY-CHEST** 

IMPRESSION NO ABNORMALITY DETECTED

**ECG** 

ECG WITHIN NORMAL LIMITS

**MEDICAL HISTORY** 

RELEVANT PRESENT HISTORY KNEE JOINT PAIN ON AND OFF.

RELEVANT PAST HISTORY NOT SIGNIFICANT RELEVANT PERSONAL HISTORY ALCOHOL - OCC.

RELEVANT FAMILY HISTORY MOTHER - HYPERTENSION / DIABETES

HISTORY OF MEDICATIONS NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.73 mts WEIGHT IN KGS. 99.8 Kgs

BMI & Weight Status as follows/sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

**GENERAL EXAMINATION** 

MENTAL / EMOTIONAL STATE NORMAL
GENERAL APPEARANCE / NUTRITIONAL HEALTHY

STATUS

BUILT / SKELETAL FRAMEWORK AVERAGE
FACIAL APPEARANCE NORMAL
SKIN LIPOMA
UPPER LIMB NORMAL
LOWER LIMB NORMAL

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

THYROID GLAND NOT ENLARGED

CAROTID PULSATION NORMAL TEMPERATURE NORMAL

PULSE 76/MIN.REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID

BRUIT

Murke

Dr. J N Shukla ,MBBS, AFIH Consultant Physician





Page 1 Of 21

View Details





Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India







Male

**PATIENT NAME: VIRENDRA SINGH REF. DOCTOR: SELF** 

ACCESSION NO: 0002WK032379 AGE/SEX :37 Years VIRENDRA SINGH :25/11/2023 08:46:01

PATIENT ID DRAWN : VIREM2711852

CLIENT PATIENT ID: RECEIVED: 25/11/2023 08:47:47 ABHA NO REPORTED :27/11/2023 12:14:42

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

**NORMAL** RESPIRATORY RATE

CARDIOVASCULAR SYSTEM

ΒP 130/86 MM HG mm/Hg

> (SUPINE) **NORMAL**

APEX BEAT **HEART SOUNDS NORMAL MURMURS ABSENT** 

**RESPIRATORY SYSTEM** 

**NORMAL** SIZE AND SHAPE OF CHEST

MOVEMENTS OF CHEST SYMMETRICAL

VESICULAR (NORMAL) BREATH SOUNDS QUALITY

ADDED SOUNDS **ABSENT** 

PER ABDOMEN

**NORMAL APPEARANCE** 

**LIVER NOT PALPABLE NOT PALPABLE SPLEEN** 

**HERNIA ABSENT** 

**CENTRAL NERVOUS SYSTEM** 

HIGHER FUNCTIONS **NORMAL** CRANIAL NERVES **NORMAL** CEREBELLAR FUNCTIONS **NORMAL** SENSORY SYSTEM **NORMAL** MOTOR SYSTEM **NORMAL** REFLEXES **NORMAL** 

**MUSCULOSKELETAL SYSTEM** 

**NORMAL SPINE NORMAL JOINTS** 

**BASIC EYE EXAMINATION** 

**NORMAL** CONJUNCTIVA NORMAL **EYELIDS NORMAL** EYE MOVEMENTS NORMAL **CORNEA** 

Dr. J N Shukla , MBBS, AFIH **Consultant Physician** 

Page 2 Of 21



Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062 Maharashtra, India







ACCESSION NO: 0002WK032379 AGE/SEX :37 Years Male VIRENDRA SINGH :25/11/2023 08:46:01

PATIENT ID : VIREM2711852 DRAWN

CLIENT PATIENT ID: RECEIVED: 25/11/2023 08:47:47 ABHA NO REPORTED :27/11/2023 12:14:42

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

DISTANT VISION RIGHT EYE WITHOUT WITHIN NORMAL LIMIT (6/6)

**GLASSES** 

WITHIN NORMAL LIMIT (6/6) DISTANT VISION LEFT EYE WITHOUT

**GLASSES** 

NEAR VISION RIGHT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT (N6) NEAR VISION LEFT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT (N6)

COLOUR VISION NORMAL (17/17)

**BASIC ENT EXAMINATION** 

**NORMAL** EXTERNAL EAR CANAL **NORMAL** TYMPANIC MEMBRANE

NOSE NO ABNORMALITY DETECTED

SINUSES **CLEAR** 

THROAT MILD CONGESTION **TONSILS NOT ENLARGED** 

SUMMARY

RELEVANT HISTORY NOT SIGNIFICANT **NOT SIGNIFICANT** RELEVANT GP EXAMINATION FINDINGS LOW RBC (4.34) RELEVANT LAB INVESTIGATIONS

> LOW PLATELET COUNT (148) RAISED EOSINOPHILS (7) RAISED CHOLESTEROL (242) RAISED TRIGLYCERIDE (194) RAISED LDL CHOLESTEROL (162)

RAISED VLDL (39.0) RAISED URIC ACID (7.6) RAISED TSH (4.840)

RELEVANT NON PATHOLOGY DIAGNOSTICS USG- GRADE I FATTY LIVER

REMARKS / RECOMMENDATIONS HYPERLIPIDEMIA, RAISED URIC ACID, RAISED TSH, LOW RBC, LOW

PLATELET

MILD EOSINOPHILS

ADV- REDUCE SATURATED FAT AND PROCESSED FOOD IN DIET

ADV- REDUCE DIAETRY PURINE

ADV- MONITOR TSH AND URIC ACID PERIODICALLY ADV- MONITOR LDL CHOLESTEROL LEVEL PERIODICALLY

FOLLOW UP WITH PHYSICIAN

Dr. J N Shukla , MBBS, AFIH Consultant Physician





Page 3 Of 21











ACCESSION NO: 0002WK032379 AGE/SEX :37 Years Male VIRENDRA SINGH

PATIENT ID : VIREM2711852

CLIENT PATIENT ID: ABHA NO

DRAWN :25/11/2023 08:46:01 RECEIVED: 25/11/2023 08:47:47 REPORTED :27/11/2023 12:14:42

**Test Report Status** Results Units <u>Final</u>

# MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

**ULTRASOUND ABDOMEN** 

**ULTRASOUND ABDOMEN** 

GRADE I FATTY LIVER.

**TMT OR ECHO** 

**CLINICAL PROFILE** 

2 DECHO DONE: IMPRESSION.

-GOOD LV SYSTOLIC FUNCTION AT REST. NO RWMA

-LVEF 55-60%.

-ALL VALVES STRUCTURALLY NORMAL.

-NO EVIDENCE OF PE/CLOT/VEGETATION

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

Dr. J N Shukla , MBBS, AFIH **Consultant Physician** 





Page 4 Of 21



Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062 Maharashtra, India







ACCESSION NO: 0002WK032379 AGE/SEX :37 Years VIRENDRA SINGH

PATIENT ID : VIREM2711852

CLIENT PATIENT ID: ABHA NO

DRAWN :25/11/2023 08:46:01 RECEIVED: 25/11/2023 08:47:47 REPORTED :27/11/2023 12:14:42

**Test Report Status** <u>Final</u> Results **Biological Reference Interval** Units

н	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECK UP B	ELOW 40 MALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)  METHOD: CYANIDE FREE DETERMINATION	13.1	13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD: FLUORESCENCE FLOW CYTOMETRY	4.34 Low	4.5 - 5.5	mil/μL
WHITE BLOOD CELL (WBC) COUNT METHOD: ELECTRICAL IMPEDANCE	6.12	4.0 - 10.0	thou/µL
PLATELET COUNT  METHOD: ELECTRONIC IMPEDENCE & MICROSCOPY	148 Low	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD: CALCULATED PARAMETER	40.0	40 - 50	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM	92.2	83.0 - 101.0	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)  METHOD: CALCULATED PARAMETER	30.1	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER	32.7	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM	14.0	11.6 - 14.0	%
MENTZER INDEX	21.2		
MEAN PLATELET VOLUME (MPV)  METHOD: DERIVED PARAMETER FROM PLATELET HISTOGRAM	13.6 High	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS  METHOD: FLUORESCENCE FLOW CYTOMETRY	51	40 - 80	%
LYMPHOCYTES  METHOD: FLUORESCENCE FLOW CYTOMETRY	34	20 - 40	%
MONOCYTES  METHOD: FLUORESCENCE FLOW CYTOMETRY	7	2 - 10	%
EOSINOPHILS METHOD: FLUORESCENCE FLOW CYTOMETRY	7 High	1 - 6	%

Dr. Sushant Chikane **Consultant Pathologist** 





Page 5 Of 21







ACCESSION NO: 0002WK032379 AGE/SEX :37 Years VIRENDRA SINGH

PATIENT ID : VIREM2711852

CLIENT PATIENT ID: ABHA NO

:25/11/2023 08:46:01 DRAWN RECEIVED: 25/11/2023 08:47:47 REPORTED :27/11/2023 12:14:42

Results	Biological Reference	Interval Units
1	0 - 1	%
3.12	2.0 - 7.0	thou/μL
2.08	1.0 - 3.0	thou/μL
0.43	0.2 - 1.0	thou/μL
0.43	0.02 - 0.50	thou/μL
0.06	0.02 - 0.10	thou/μL
1.5		
PREDOMINANTLY N	IORMOCYTIC NORMOCHROMIC	
NORMAL MORPHO	∟OGY	
MILDLY REDUCED	IN SMEAR.	
	1 3.12 2.08 0.43 0.43 0.06 1.5  PREDOMINANTLY N	1 0 - 1 3.12 2.0 - 7.0 2.08 1.0 - 3.0 0.43 0.2 - 1.0 0.43 0.02 - 0.50 0.06 0.02 - 0.10

Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients 

A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.

Dr. Sushant Chikane **Consultant Pathologist** 





Page 6 Of 21



Patient Ref. No. 2000012092780





**REF. DOCTOR: SELF PATIENT NAME: VIRENDRA SINGH** 

ACCESSION NO: 0002WK032379 AGE/SEX :37 Years Male VIRENDRA SINGH

PATIENT ID : VIREM2711852

CLIENT PATIENT ID: ABHA NO

:25/11/2023 08:46:01 DRAWN RECEIVED: 25/11/2023 08:47:47 REPORTED :27/11/2023 12:14:42

**Test Report Status Biological Reference Interval** <u>Final</u> Results Units

#### **HAEMATOLOGY**

#### MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

## **ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD**

mm at 1 hr E.S.R = or < 10

METHOD: MODIFIED WESTERGREN METHOD BY AUTOMATED ANALYSER

## GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD**

HBA1C 5.1 Non-diabetic Adult < 5.7 %

Pre-diabetes 5.7 - 6.4

Diabetes diagnosis: > or = 6.5Therapeutic goals: < 7.0 Action suggested: > 8.0

(ADA Guideline 2021)

METHOD: ION-EXCHANGE HPLC

ESTIMATED AVERAGE GLUCOSE(EAG) 99.7 < 116 mg/dL

## Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-**TEST DESCRIPTION**:Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change

# TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging.
Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. **Decreased** in: Polycythermia vera, Sickle cell anemia

# LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.3. Identifying patients at increased risk for diabetes (prediabetes).

Dr. Sushant Chikane Consultant Pathologist Page 7 Of 21





# **PERFORMED AT:**

Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062 Maharashtra, India







ACCESSION NO: 0002WK032379 AGE/SEX VIRENDRA SINGH

PATIENT ID : VIREM2711852

CLIENT PATIENT ID: ABHA NO

:25/11/2023 08:46:01 DRAWN RECEIVED: 25/11/2023 08:47:47

:37 Years

REPORTED :27/11/2023 12:14:42

**Test Report Status** Results **Biological Reference Interval** <u>Final</u> Units

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

- eAG gives an evaluation of blood glucose levels for the last couple of months.
   eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c 46.7

## HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.
  3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

  4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr. Sushant Chikane **Consultant Pathologist** 





Page 8 Of 21







ACCESSION NO: 0002WK032379 AGE/SEX :37 Years VIRENDRA SINGH

PATIENT ID : VIREM2711852

CLIENT PATIENT ID: ABHA NO

DRAWN :25/11/2023 08:46:01 RECEIVED: 25/11/2023 08:47:47

REPORTED :27/11/2023 12:14:42

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

## **IMMUNOHAEMATOLOGY**

# MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

**ABO GROUP & RH TYPE, EDTA WHOLE BLOOD** 

**ABO GROUP** Α

METHOD: HAEMAGGLUTINATION (AUTOMATED)

RH TYPE **POSITIVE** 

METHOD: HAEMAGGLUTINATION (AUTOMATED)

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

Dr. Sushant Chikane **Consultant Pathologist**  Page 9 Of 21











ACCESSION NO: **0002WK032379**AGE/SEX: 37 Years Male VIRENDRA SINGH

PATIENT ID : VIREM2711852

CLIENT PATIENT ID: ABHA NO : DRAWN :25/11/2023 08:46:01
RECEIVED :25/11/2023 08:47:47
REPORTED :27/11/2023 12:14:42

Test Report Status <u>Final</u> Results Biological Reference Interval Units

**BIOCHEMISTRY** 

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

**GLUCOSE FASTING, FLUORIDE PLASMA** 

FBS (FASTING BLOOD SUGAR) 91 Normal <100 mg/dL

Impaired fasting glucose:100 to

125

Diabetes mellitus: > = 126 (on

more than 1 occassion) (ADA guidelines 2021)

METHOD: SPECTROPHOTOMETRY HEXOKINASE

**GLUCOSE, POST-PRANDIAL, PLASMA** 

PPBS(POST PRANDIAL BLOOD SUGAR) 78 Normal <140 mg/dL

Impaired glucose tolerance:140 to 199 Diabetes mellitus: > = 200 (on more than 1 occassion)

ADA guideline 2021

METHOD: SPECTROPHOTOMETRY HEXOKINASE

LIPID PROFILE WITH CALCULATED LDL

CHOLESTEROL, TOTAL **242 High** Desirable: < 200 mg/dL

Borderline : 200 - 239 High : > / = 240

METHOD: SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - CHOLETSEROL OXIDASE, ESTERASE, PEROXIDASE

TRIGLYCERIDES 194 High Normal: < 150 mg/dL

Borderline high: 150 - 199

High: 200 - 499 Very High: >/= 500

METHOD : SPECTROPHOTOMETRY, ENZYMATIC ENDPOINT WITH GLYCEROL BLANK

HDL CHOLESTEROL 41 At Risk: < 40 mg/dL

Desirable: > or = 60

 ${\tt METHOD: SPECTROPHOTOMETRY, HOMOGENEOUS DIRECT ENZYMATIC COLORIMETRIC}\\$ 

CHOLESTEROL LDL **162 High** Optimal: < 100 mg/dL

Near optimal/above optimal:

100-129

Borderline high: 130-159

High: 160-189 Very high: = 190

METHOD : CALCULATED PARAMETER

Dama

Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist



Dr. Deepak Sanghavi Chief Of Lab - Mumbai Refrence Lab





Page 10 Of 21

View Details

View Report







ACCESSION NO: **0002WK032379**AGE/SEX: 37 Years Male VIRENDRA SINGH

PATIENT ID : VIREM2711852 DRAWN :25/11/2023 08:46:01

CLIENT PATIENT ID: RECEIVED : 25/11/2023 08:47:47
ABHA NO : REPORTED : 27/11/2023 12:14:42

Test Report Status <u>Final</u> Results Biological Reference Interval Units

NON HDL CHOLESTEROL **201 High** Desirable: < 130 mg/dL

Above Desirable: 130 -159 Borderline High: 160 - 189

High: 190 - 219

Very high : > / = 220

METHOD: CALCULATED PARAMETER

VERY LOW DENSITY LIPOPROTEIN **39.0 High** < or = 30.0 mg/dL

METHOD: CALCULATED PARAMETER

CHOL/HDL RAΠΟ **5.9 High** Low Risk : 3.3 - 4.4

Average Risk : 4.5 - 7.0 Moderate Risk : 7.1 - 11.0

High Risk : > 11.0

LDL/HDL RATIO 4.3 High Desirable/Low Risk: 0.5 - 3.0

Borderline/Moderate Risk: 3.1

- 6.0

High Risk: > 6.0

METHOD: CALCULATED PARAMETER

METHOD: CALCULATED PARAMETER

## Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category						
Extreme risk group	A.CAD with > 1 feature of high risk group					
	B. CAD with > 1 feature of Very high risk g	group or recurrent ACS (within 1 year) despite LDL-C < or =				
	50 mg/dl or polyvascular disease					
Very High Risk	1. Established ASCVD 2. Diabetes with 2 r	najor risk factors or evidence of end organ damage 3.				
	Familial Homozygous Hypercholesterolemia	A				
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ					
"	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary					
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque					
Moderate Risk	2 major ASCVD risk factors					
Low Risk	0-1 major ASCVD risk factors					
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors						
1. Age > or = 45 year	= 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use					
2. Family history of p	history of premature ASCVD 4. High blood pressure					
5. Low HDL						

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)

Dama

Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist



Dr. Deepak Sanghavi Chief Of Lab - Mumbai Refrence Lab





Page 11 Of 21

/iew Details

View Report



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India







ACCESSION NO: 0002WK032379 AGE/SEX :37 Years VIRENDRA SINGH

PATIENT ID : VIREM2711852

CLIENT PATIENT ID: ABHA NO

DRAWN :25/11/2023 08:46:01 RECEIVED: 25/11/2023 08:47:47 REPORTED :27/11/2023 12:14:42

**Test Report Status Results Biological Reference Interval** Units <u>Final</u>

Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR = 30)	<or 60)<="" =="" td=""><td></td><td></td></or>		
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or></td></or>	<or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

<sup>\*</sup>After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

# LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL  METHOD: SPECTROPHOTOMETRY, COLORIMETRIC -DIAZO METHOD	0.51	Upto 1.2	mg/dL
BILIRUBIN, DIRECT  METHOD: SPECTROPHOTOMETRY, JENDRASSIK & GROFF - DIAZOTIZ	0.22 Zation	< or = 0.3	mg/dL
BILIRUBIN, INDIRECT METHOD: CALCULATED PARAMETER	0.25	0.0 - 0.9	mg/dL
TOTAL PROTEIN  METHOD: SPECTROPHOTOMETRY, COLORIMETRIC -BIURET, REAGEN	6.9 IT BLANK, SERUM BLANK	6.0 - 8.0	g/dL
ALBUMIN  METHOD: SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DY	4.8 YE BINDING	3.97 - 4.94	g/dL
GLOBULIN METHOD: CALCULATED PARAMETER	2.1	2.0 - 3.5	g/dL
ALBUMIN/GLOBULIN RATIO METHOD: CALCULATED PARAMETER	2.3 High	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT)  METHOD: SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE	22 E ACTIVATION( P5P) - IFCC	Upto 40	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT)  METHOD: SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE	25 E ACTIVATION( P5P) - IFCC	Upto 41	U/L
ALKALINE PHOSPHATASE  METHOD: SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC	81	40 - 129	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT)  METHOD: SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - G-G	21 SLUTAMYL-CARBOXY-NITROANILIDE -	< 60	U/L
LACTATE DEHYDROGENASE  METHOD: SPECTROPHOTOMETRY, LACTATE TO PYRUVATE - UV-IFCC	184	< 232	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	14	6 - 20	mg/dL



Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) **Consultant Pathologist** 



Dr. Deepak Sanghavi Chief Of Lab - Mumbai Refrence Lab





Page 12 Of 21

# **PERFORMED AT:**

Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062 Maharashtra, India







Male

PATIENT NAME: VIRENDRA SINGH REF. DOCTOR: SELF

ACCESSION NO: 0002WK032379 AGE/SEX
VIRENDRA SINGH

PATIENT ID : VIREM2711852

CLIENT PATIENT ID: ABHA NO : DRAWN :25/11/2023 08:46:01
RECEIVED :25/11/2023 08:47:47
REPORTED :27/11/2023 12:14:42

:37 Years

Test Report Status <u>Final</u> Results Biological Reference Interval Units

METHOD: SPECTROPHOTOMETRY, UREASE -COLORIMETRIC

CREATININE, SERUM

CREATININE 1.15 0.90 - 1.30 mg/dL

METHOD: SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE KINETIC - RATE BLANKED - IFCC-IDMS STANDARIZED

**BUN/CREAT RATIO** 

BUN/CREAT RATIO 11.80 8 - 15

METHOD: CALCULATED PARAMETER

**URIC ACID, SERUM** 

URIC ACID **7.6 High** 3.4 - 7.0 mg/dL

METHOD: SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC- URICASE

**TOTAL PROTEIN, SERUM** 

TOTAL PROTEIN 6.9 6.0 - 8.0 g/dL

METHOD: SPECTROPHOTOMETRY, COLORIMETRIC-BIURET, REAGENT BLANK, SERUM BLANK

**ALBUMIN, SERUM** 

ALBUMIN 4.8 3.97 - 4.94 q/dL

 ${\tt METHOD}: {\tt SPECTROPHOTOMETRY, BROMOCRESOL\ GREEn(BCG)} \ \hbox{-} \ {\tt DYE\ BINDING}$ 

**GLOBULIN** 

GLOBULIN 2.1 2.0 - 3.5 g/dL

METHOD : CALCULATED PARAMETER

**ELECTROLYTES (NA/K/CL), SERUM** 

SODIUM, SERUM 140 136 - 145 mmol/L

METHOD: ISE INDIRECT

POTASSIUM, SERUM 4.90 3.5 - 5.1 mmol/L

METHOD : ISE INDIRECT

CHLORIDE, SERUM 104 98 - 106 mmol/L

METHOD : ISE INDIRECT
Interpretation(s)

Sodium Potassium Chloride

Dama

Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist



Dr. Deepak Sanghavi Chief Of Lab - Mumbai Refrence Lab



Page 13 Of 21

View Details

View Report



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India







:25/11/2023 08:46:01

**REF. DOCTOR: SELF PATIENT NAME: VIRENDRA SINGH** 

ACCESSION NO: 0002WK032379 AGE/SEX :37 Years Male VIRENDRA SINGH

PATIENT ID : VIREM2711852

CLIENT PATIENT ID: RECEIVED: 25/11/2023 08:47:47 REPORTED :27/11/2023 12:14:42 ABHA NO

DRAWN

**Test Report Status** Results **Biological Reference Interval Final** Units

Decreased in:CCF.cirrhosis. Decreased in: Low potassium Decreased in: Vomiting, diarrhea, vomiting, diarrhea, excessive intake,prolonged vomiting or diarrhea, renal failure combined with salt sweating, salt-losing RTA types I and II, deprivation, over-treatment with nephropathy, adrenal insufficiency, hyperaldosteronism, Cushing's diuretics, chronic respiratory acidosis, nephrotic syndrome, water syndrome,osmotic diuresis (e.g. diabetic ketoacidosis, excessive intoxication, SIADH. Drugs: hyperglycemia), alkalosis, familial sweating, SIADH, salt-losing thiazides, diuretics, ACE inhibitors, periodic paralysis,trauma nephropathy, porphyria, expansion of chlorpropamide,carbamazepine,anti (transient).Drugs: Adrenergic agents, extracellular fluid volume, depressants (SSRI), antipsychotics. diuretics. adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative,corticosteroids, diuretics. Increased in: Dehydration Increased in: Renal failure, nephrotic Increased in: Massive hemolysis, (excessivesweating, severe severe tissue damage, rhabdomyolysis, syndrome, RTA, dehydration, vomiting or diarrhea), diabetes acidosis, dehydration, renal failure, overtreatment with Addison's disease, RTA type IV, mellitus, diabetesinsipidus, saline, hyperparathyroidism, diabetes hyperaldosteronism, inadequate hyperkalemic familial periodic insipidus, metabolic acidosis from water intake. Drugs: steroids. diarrhea (Loss of HCO3-), respiratory paralysis. Drugs: potassium salts. licorice.oral contraceptives. potassium- sparing diuretics, NSAIDs, alkalosis, hyperadrenocorticism, beta-blockers, ACE inhibitors, high-Drugs: acetazolamide, androgens, dose trimethoprim-sulfamethoxazole hydrochlorothiazide, salicylates. Interferences: Severe lipemia or Interferences: Hemolysis of sample, Interferences:Test is helpful in hyperproteinemi, if sodium analysis delayed separation of serum, assessing normal and increased anion involves a dilution step can cause prolonged fist clenching during blood gap metabolic acidosis and in spurious results. The serum sodium drawing, and prolonged tourniquet distinguishing hypercalcemia due to falls about 1.6 mEq/L for each 100 placement. Very high WBC/PLT counts hyperparathyroidism (high serum may cause spurious. Plasma potassium mg/dL increase in blood glucose. chloride) from that due to malignancy levels are normal. (Normal serum chloride)

## Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within

individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment,Renal Glyosuria,Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, is chemia to the liver, chronic



Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) **Consultant Pathologist** 



Dr. Deepak Sanghavi Chief Of Lab - Mumbai Refrence Lab





Page 14 Of 21



Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062 Maharashtra, India







ACCESSION NO: 0002WK032379 AGE/SEX :37 Years VIRENDRA SINGH

PATIENT ID : VIREM2711852

CLIENT PATIENT ID: ABHA NO

:25/11/2023 08:46:01 DRAWN RECEIVED: 25/11/2023 08:47:47

REPORTED :27/11/2023 12:14:42

**Test Report Status** Results **Biological Reference Interval** <u>Final</u> Units

hepatitis, obstruction of bile ducts, cirrhosis

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

**GGT** is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic

syndrome, Protein-losing enteropathy etc. **Albumin** is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels: Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic

syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. **Higher-than-normal levels may be due to:** Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) **Consultant Pathologist** 

Dr. Deepak Sanghavi Chief Of Lab - Mumbai Refrence Lab



Page 15 Of 21



Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062 Maharashtra, India







ACCESSION NO: **0002WK032379**AGE/SEX: 37 Years Male VIRENDRA SINGH

PATIENT ID : VIREM2711852

CLIENT PATIENT ID: ABHA NO : DRAWN :25/11/2023 08:46:01 RECEIVED :25/11/2023 08:47:47 REPORTED :27/11/2023 12:14:42

Test Report Status Final Results Biological Reference Interval Units

## **CLINICAL PATH - URINALYSIS**

## MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

APPEARANCE CLEAR

**CHEMICAL EXAMINATION, URINE** 

PH 6.5 5.00 - 7.50 1.020 1.010 - 1.030 SPECIFIC GRAVITY **PROTEIN** NOT DETECTED **NOT DETECTED GLUCOSE** NOT DETECTED NOT DETECTED **KETONES** NOT DETECTED NOT DETECTED **BLOOD** NOT DETECTED NOT DETECTED **BILIRUBIN** NOT DETECTED NOT DETECTED

UROBILINOGEN NOT DETECTED

NITRITE NOT DETECTED NOT DETECTED

LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS

NOT DETECTED

NOT DETECTED

/HPF
PUS CELL (WBC'S)

1-2

0-5

/HPF
EPITHELIAL CELLS

0-1

0-5

/HPF

CASTS NOT DETECTED
CRYSTALS NOT DETECTED

BACTERIA NOT DETECTED NOT DETECTED
YEAST NOT DETECTED NOT DETECTED

 ${\tt METHOD: URINE\ 8. MICROSCOPY\ EXAMINATION\ BY\ INTEGRATED\ AUTOMATED\ SYSTEM}$ 

# Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions		
Proteins	Inflammation or immune illnesses		
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment		

Ds/.

Dr. Deepak Sanghavi Chief Of Lab - Mumbai Refrence Lab



Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist





Page 16 Of 21

View Details



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India







ACCESSION NO: 0002WK032379 AGE/SEX :37 Years VIRENDRA SINGH

PATIENT ID : VIREM2711852

CLIENT PATIENT ID: ABHA NO

DRAWN :25/11/2023 08:46:01 RECEIVED: 25/11/2023 08:47:47 REPORTED :27/11/2023 12:14:42

**Test Report Status** <u>Final</u> Results Biological Reference Interval Units

Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Deepak Sanghavi Chief Of Lab - Mumbai Refrence Lab

Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist





Page 17 Of 21





Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062 Maharashtra, India







ACCESSION NO: **0002WK032379**AGE/SEX: 37 Years Male VIRENDRA SINGH

PATIENT ID : VIREM2711852

CLIENT PATIENT ID: ABHA NO : DRAWN :25/11/2023 08:46:01 RECEIVED :25/11/2023 08:47:47 REPORTED :27/11/2023 12:14:42

Test Report Status <u>Final</u> Results Biological Reference Interval Units

# **CLINICAL PATH - STOOL ANALYSIS**

## MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

PHYSICAL EXAMINATION, STOOL

COLOUR BROWN

CONSISTENCY SEMI FORMED

MUCUS NOT DETECTED NOT DETECTED

VISIBLE BLOOD ABSENT ABSENT ABSENT

ADULT PARASITE NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

CHEMICAL EXAMINATION, STOOL

STOOL PH 6.0

OCCULT BLOOD NOT DETECTED NOT DETECTED

METHOD: MODIFIED GUAIAC METHOD

MICROSCOPIC EXAMINATION, STOOL

PUS CELLS NOT DETECTED /hpf

RED BLOOD CELLS NOT DETECTED NOT DETECTED /HPF

METHOD: MICROSCOPIC EXAMINATION

CYSTS NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

OVA NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

LARVAE NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

TROPHOZOITES NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

FAT ABSENT CHARCOT LEYDEN CRYSTALS ABSENT

Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION			
Pus cells	Pus in the stool is an indication of infection			

Swary

Dr Sukanya Verma (MBBS,MD,DNB) (Reg.No.MMC2012/03/0443) Consultant Microbiologist



Page 18 Of 21

/iew Details



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India







ACCESSION NO: 0002WK032379 AGE/SEX :37 Years Male VIRENDRA SINGH

PATIENT ID : VIREM2711852

CLIENT PATIENT ID: ABHA NO

:25/11/2023 08:46:01 RECEIVED: 25/11/2023 08:47:47 REPORTED :27/11/2023 12:14:42

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as			
	ulcerative colitis			
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects			
	presence of parasitic infestation of gastrointestinal tract. Various forms of			
	parasite that can be detected include cyst, trophozoite and larvae. One negative			
	result does not rule out the possibility of parasitic infestation. Intermittent			
	shedding of parasites warrants examinations of multiple specimens tested on			
	consecutive days. Stool specimens for parasitic examination should be collected			
	before initiation of antidiarrheal therapy or antiparasitic therapy. This test does			
	not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia			
	and Isospora species. Examination of Ova and Parasite has been carried out by			
	direct and concentration techniques.			
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to			
	bacteria or viruses.			
Charcot-Leyden crystal	Parasitic diseases.			
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.			
Frank blood	Bleeding in the rectum or colon.			
Occult blood	Occult blood indicates upper GI bleeding.			
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.			
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up			
	in stool when there is inflammation or infection.			
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.			
pH	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an			
	acidic stool.			

# ADDITIONAL STOOL TESTS:

- Stool Culture: This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if treatment for GI infection worked.
- Fecal Calprotectin: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS).
- 3. Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia.
- Clostridium Difficile Toxin Assay: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to overuse of broad spectrum antibiotics which alter the normal GI flora.
- Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array 5. Test (Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus, parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
- Rota Virus Immunoassay: This test is recommended in severe gastroenteritis in infants & children associated with watery diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.

Dr Sukanya Verma (MBBS,MD,DNB) (Reg.No.MMC2012/03/0443) **Consultant Microbiologist** 





Page 19 Of 21







ACCESSION NO: **0002WK032379**AGE/SEX: 37 Years Male VIRENDRA SINGH

PATIENT ID : VIREM2711852

CLIENT PATIENT ID: ABHA NO : DRAWN :25/11/2023 08:46:01
RECEIVED :25/11/2023 08:47:47
REPORTED :27/11/2023 12:14:42

Test Report Status <u>Final</u> Results Biological Reference Interval Units

## **SPECIALISED CHEMISTRY - HORMONE**

# MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

# THYROID PANEL, SERUM

T3 112.0 80.0 - 200.0 ng/dL

METHOD: COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNOASSAY

T4 6.85 5.10 - 14.10  $\mu g/dL$ 

METHOD: COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNOASSAY

TSH (ULTRASENSITIVE) **4.840 High** 0.270 - 4.200 µIU/mL

METHOD: SANDWICH ELECTROCHEMILUMINESCENCE IMMUNOASSAY

# Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
		-	-	-	(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism

Ds/.

Dr. Deepak Sanghavi Chief Of Lab - Mumbai Refrence Lab Dama

Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist





Page 20 Of 21

View Details

View Report



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India







ACCESSION NO: **0002WK032379**AGE/SEX: 37 Years Male VIRENDRA SINGH

PATIENT ID : VIREM2711852

CLIENT PATIENT ID: ABHA NO : DRAWN :25/11/2023 08:46:01
RECEIVED :25/11/2023 08:47:47
REPORTED :27/11/2023 12:14:42

Test Report Status <u>Final</u> Results Biological Reference Interval Units

8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011.

NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

\*\*End Of Report\*\*
Please visit www.agilusdiagnostics.com for related Test Information for this accession

## **CONDITIONS OF LABORATORY TESTING & REPORTING**

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
  - i. Specimen received is insufficient or inappropriate
  - ii. Specimen quality is unsatisfactory
  - iii. Incorrect specimen type
  - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

# **Agilus Diagnostics Ltd**

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



Dr. Deepak Sanghavi Chief Of Lab - Mumbai Refrence Lab



Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist





Page 21 Of 21

View Details

Niew Denem



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India

